Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42875 | 0.89 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL29386113 | 0.89 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL29592639 | 0.82 | KMT2A (0.33) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL8931556 | 0.79 | SMN1; SMN2 (0.49) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| 2-Mercaptopyridine SCHEMBL28679755 | 0.78 | KMT2A (0.35) | MAPTSMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL8816003 | 0.77 | POLB (0.60) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL23086185 | 0.76 | SMN1; SMN2 (0.41) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL342420 | 0.76 | POLB (0.45) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL24478175 | 0.75 | ALDH1A1 (0.34) | MAPTALDH1A1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL12727641 | 0.75 | POLB (0.49) | ALDH1A1SMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168426-A1 | COMPOSITIONS AND CELLS CONTAINING MIXTURES OF OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11725041-B2 | Immune-modulating compounds | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2023-08-15 | — | — | US | disclosed |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2023-06-29 | — | — | US | disclosed |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | HALOZYME, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022216734-A1 | MULTIVALENT CHOLERA MULTIEPITOPE FUSION ANTIGEN (MEFA) AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-10-13 | — | — | WO | disclosed |
| US-10385108-B2 | Peptide analogs of alpha-melanocyte stimulating hormone | GENZYME CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3207130-B1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | HALOZYME INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2816055-B1 | Peptide analogs of alpha-melanocyte stimulating hormons | GENZYME CORP (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10053504-B2 | SPARC binding ScFvs | ABRAXIS BIOSCIENCE, LLC (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180216095-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | DADA2 FOUNDATION | 2018-08-02 | — | — | US | disclosed |
| US-6232107-B1 | NUCLEOTIDE SEQUENCE CODING GREEN FLUORESCENT PROTEIN; FOR USE IN DIAGNOSIS OF MICROORGANISM INFECTION | Bryan, Bruce J. | 2001-05-15 | — | — | US | disclosed |
| WO-2001002600-A2 | DETECTION OF ANALYTES USING ATTENUATED ENZYMES | GENERAL ATOMICS (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6037329-A | GENE DELIVERY COMPOSITION COMPRISING POLYPEPTIDE THAT BINDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-NUCLEIC ACID BINDING DOMAIN-NUCLEIC ACID MOLECULE | SELECTIVE GENETICS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0923387-A2 | HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES | Selective Genetics, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997049434-A9 | HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES | — | 1998-05-07 | — | — | WO | disclosed |
| WO-1997049434-A2 | HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES | PRIZM PHARMACEUTICALS, INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0776218-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996008274-A2 | CONJUGATES OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR WITH TARGETED AGENTS | PRIZM PHARMACEUTICALS, INC. (US) | 1996-03-21 | — | — | WO | disclosed |
| WO-1996006641-A1 | CONJUGATES OF VASCULAR ENDOTHELIAL GROWTH FACTOR WITH TARGETED AGENTS | PRIZM PHARMACEUTICALS, INC. (US) | 1996-03-07 | — | — | WO | disclosed |
| WO-1995024928-A2 | HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS | PRIZM PHARMACEUTICALS, INC. (US) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180216095-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | MAPT 4133/4885ALDH1A1 339/4885SMN1; SMN2 1357/4885 |
| US-11584923-B2 | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same | ADA, CDA, ADAR | MAPT 4133/4885ALDH1A1 339/4885SMN1; SMN2 1357/4885 |
| US-20230203470-A1 | COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME | ADA, CDA, ADAR | MAPT 4133/4885ALDH1A1 339/4885SMN1; SMN2 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.